Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $HIMS
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/18/2025 | $42.00 → $60.00 | Overweight → Equal-Weight | Morgan Stanley |
1/10/2025 | $24.00 → $25.00 | Neutral → Sell | Citigroup |
1/7/2025 | $35.00 | Buy | BTIG Research |
12/17/2024 | $42.00 | Overweight | Morgan Stanley |
11/14/2024 | Buy → Underperform | BofA Securities | |
8/22/2024 | $24.00 | Buy | Needham |
8/9/2024 | Outperform → In-line | Imperial Capital | |
5/22/2024 | $16.00 → $20.00 | Buy → Neutral | Citigroup |
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers
MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ:RKLB) and Hims & Hers Health Inc. (NYSE:HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account. RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results tha
Define Ventures Appoints Carolyn Magill as Venture Partner
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Hims & Hers Health downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously
Hims & Hers Health downgraded by Citigroup with a new price target
Citigroup downgraded Hims & Hers Health from Neutral to Sell and set a new price target of $25.00 from $24.00 previously
BTIG Research initiated coverage on Hims & Hers Health with a new price target
BTIG Research initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00
Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Chief Operating Officer Baird Melissa exercised 67,687 shares at a strike of $0.40 and sold $2,358,145 worth of shares (67,687 units at $34.84) (SEC Form 4)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Chief Financial Officer Okupe Oluyemi sold $749,176 worth of shares (23,118 units at $32.41), decreasing direct ownership by 15% to 129,248 units (SEC Form 4)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Chief Executive Officer Dudum Andrew exercised 301,646 shares at a strike of $1.01, covered exercise/tax liability with 97,551 shares and sold $8,618,493 worth of shares (254,421 units at $33.87), decreasing direct ownership by 3% to 94,895 units (SEC Form 4)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
SEC Form 144 filed by Hims & Hers Health Inc.
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
SEC Form S-8 filed by Hims & Hers Health Inc.
S-8 - Hims & Hers Health, Inc. (0001773751) (Filer)
SEC Form 10-K filed by Hims & Hers Health Inc.
10-K - Hims & Hers Health, Inc. (0001773751) (Filer)
Define Ventures Appoints Carolyn Magill as Venture Partner
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
Former FDA deputy commissioner and former Pfizer & Hillrom quality executive join Hims & Hers, deepening the leadership that drives the company's high standard of quality and safety Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality,
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con
Hims & Hers Acquires US-based Peptide Facility
The acquisition will strengthen the long-term durability of the company's domestic supply chain, helping to ensure Americans can consistently access personalized medications Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options. This press release features multimedia. View the fu
Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219392487/en/The ac
Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)